JP2016519658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519658A5 JP2016519658A5 JP2016502221A JP2016502221A JP2016519658A5 JP 2016519658 A5 JP2016519658 A5 JP 2016519658A5 JP 2016502221 A JP2016502221 A JP 2016502221A JP 2016502221 A JP2016502221 A JP 2016502221A JP 2016519658 A5 JP2016519658 A5 JP 2016519658A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- immunogen
- rsv
- seq
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims description 193
- 241000724205 Rice stripe tenuivirus Species 0.000 claims description 181
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 116
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 67
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 235000018417 cysteine Nutrition 0.000 claims description 59
- 238000006467 substitution reaction Methods 0.000 claims description 59
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 55
- 239000002105 nanoparticle Substances 0.000 claims description 55
- 239000013598 vector Substances 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 230000004927 fusion Effects 0.000 claims description 27
- 238000008416 Ferritin Methods 0.000 claims description 26
- 102000008857 Ferritin Human genes 0.000 claims description 24
- 108050000784 Ferritin Proteins 0.000 claims description 24
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 24
- 238000011534 incubation Methods 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 20
- 238000005829 trimerization reaction Methods 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 15
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims description 15
- 101710204410 Scaffold protein Proteins 0.000 claims description 15
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 101000868165 Acidianus ambivalens Sulfur oxygenase/reductase Proteins 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 7
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 6
- 241000711920 Human orthopneumovirus Species 0.000 claims description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 241000711895 Bovine orthopneumovirus Species 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 230000029662 T-helper 1 type immune response Effects 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 150000001945 cysteines Chemical class 0.000 claims description 4
- -1 encapsulin Proteins 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000013638 trimer Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 241000712005 Bovine respirovirus 3 Species 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711408 Murine respirovirus Species 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- 102100037224 Noncompact myelin-associated protein Human genes 0.000 claims description 2
- 101710184695 Noncompact myelin-associated protein Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 102220616746 Son of sevenless homolog 1_C31S_mutation Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims description 2
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 230000012743 protein tagging Effects 0.000 claims description 2
- 238000012857 repacking Methods 0.000 claims description 2
- 102200114232 rs62637020 Human genes 0.000 claims description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 101800002712 p27 Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780910P | 2013-03-13 | 2013-03-13 | |
| US61/780,910 | 2013-03-13 | ||
| US201361798389P | 2013-03-15 | 2013-03-15 | |
| US61/798,389 | 2013-03-15 | ||
| US201361857613P | 2013-07-23 | 2013-07-23 | |
| US61/857,613 | 2013-07-23 | ||
| US201361863909P | 2013-08-09 | 2013-08-09 | |
| US61/863,909 | 2013-08-09 | ||
| PCT/US2014/026714 WO2014160463A1 (en) | 2013-03-13 | 2014-03-13 | Prefusion rsv f proteins and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020021468A Division JP7043530B2 (ja) | 2013-03-13 | 2020-02-12 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519658A JP2016519658A (ja) | 2016-07-07 |
| JP2016519658A5 true JP2016519658A5 (enExample) | 2017-04-13 |
| JP6703475B2 JP6703475B2 (ja) | 2020-06-03 |
Family
ID=51625430
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502221A Active JP6703475B2 (ja) | 2013-03-13 | 2014-03-13 | 融合前ｒｓｖｆタンパク質およびそれらの使用 |
| JP2020021468A Active JP7043530B2 (ja) | 2013-03-13 | 2020-02-12 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
| JP2022041006A Active JP7503588B2 (ja) | 2013-03-13 | 2022-03-16 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
| JP2024093392A Pending JP2024107243A (ja) | 2013-03-13 | 2024-06-10 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020021468A Active JP7043530B2 (ja) | 2013-03-13 | 2020-02-12 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
| JP2022041006A Active JP7503588B2 (ja) | 2013-03-13 | 2022-03-16 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
| JP2024093392A Pending JP2024107243A (ja) | 2013-03-13 | 2024-06-10 | 融合前ｒｓｖ ｆタンパク質およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10017543B2 (enExample) |
| EP (2) | EP4421177A3 (enExample) |
| JP (4) | JP6703475B2 (enExample) |
| KR (3) | KR102450375B1 (enExample) |
| CN (2) | CN105473604B (enExample) |
| AU (5) | AU2014243756B2 (enExample) |
| CA (2) | CA2902877C (enExample) |
| DK (1) | DK2970398T3 (enExample) |
| ES (1) | ES2981623T3 (enExample) |
| FI (1) | FI2970398T3 (enExample) |
| HR (1) | HRP20240996T1 (enExample) |
| HU (1) | HUE067333T2 (enExample) |
| LT (1) | LT2970398T (enExample) |
| MX (2) | MX385818B (enExample) |
| PL (1) | PL2970398T3 (enExample) |
| PT (1) | PT2970398T (enExample) |
| RS (1) | RS65760B1 (enExample) |
| RU (1) | RU2761631C2 (enExample) |
| SI (1) | SI2970398T1 (enExample) |
| SM (1) | SMT202400297T1 (enExample) |
| WO (1) | WO2014160463A1 (enExample) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| RS60056B1 (sr) | 2013-02-01 | 2020-04-30 | Medimmune Llc | Epitopi f proteina respiratornog sincicijalnog virusa |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP4421177A3 (en) * | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| CN105189756B (zh) | 2013-03-14 | 2021-06-11 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
| KR20240122922A (ko) | 2013-03-27 | 2024-08-13 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| JP2016533332A (ja) * | 2013-09-24 | 2016-10-27 | マサチューセッツ インスティテュート オブ テクノロジー | 自己集合型ナノ粒子ワクチン |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| EP3247388B1 (en) | 2015-01-20 | 2025-09-10 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof |
| WO2016122414A1 (en) * | 2015-01-29 | 2016-08-04 | Agency For Science, Technology And Research | Nanocapsules carrying chikungunya-associated peptides |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| CN107847580B (zh) * | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| FR3041962B1 (fr) * | 2015-10-01 | 2018-01-05 | Lab Francais Du Fractionnement | Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie |
| US20180271970A1 (en) | 2015-10-22 | 2018-09-27 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| SG11201803581VA (en) | 2015-10-29 | 2018-05-30 | Univ Emory | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
| RU2723039C2 (ru) * | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Мутанты белка f rsv |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| CN115960263A (zh) * | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
| AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| MX2018012094A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas. |
| IL245059A0 (en) | 2016-04-12 | 2016-06-30 | Technion Res & Dev Foundation | Electrospun scaffolds from extracellular matrix |
| SG11201810078PA (en) * | 2016-05-30 | 2018-12-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| EP3474893A1 (en) | 2016-06-27 | 2019-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| CN106119287B (zh) * | 2016-08-29 | 2019-10-11 | 广东华南疫苗股份有限公司 | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 |
| US10842862B2 (en) | 2016-10-03 | 2020-11-24 | University Of Massachusetts | Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV) |
| WO2018081289A2 (en) | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion piv f immunogens and their use |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018175518A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv) |
| EP3606942B1 (en) | 2017-04-04 | 2025-06-11 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| GB2600652B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel compositions |
| JP7356911B2 (ja) * | 2017-06-14 | 2023-10-05 | ヴァイロメティックス アーゲー | 呼吸器合胞体ウイルスに対する予防のための環状ペプチド |
| CN111405907B (zh) * | 2017-08-07 | 2024-10-01 | 考尔德生物科技有限公司 | 构象稳定的rsv预融合f蛋白 |
| AU2018333566A1 (en) | 2017-09-15 | 2020-02-27 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| JP2019092481A (ja) * | 2017-11-27 | 2019-06-20 | 国立大学法人東京工業大学 | ヘテロタンパク質ケージ |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| WO2019147749A2 (en) | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| CN112088014B (zh) | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
| WO2019178521A1 (en) * | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| JP7614841B2 (ja) * | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| JP2021519600A (ja) * | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | 抗原性インフルエンザ−フェリチンポリペプチド |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| CN119735681A (zh) | 2018-04-25 | 2025-04-01 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| US12433944B2 (en) | 2018-05-04 | 2025-10-07 | SpyBiotech Limited | Vaccine composition |
| CN110684747B (zh) | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| CN112566654A (zh) * | 2018-07-31 | 2021-03-26 | 葛兰素史密丝克莱恩生物有限公司 | 抗原纯化方法 |
| AU2019315602B2 (en) | 2018-08-03 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nipah virus immunogens and their use |
| BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
| US20200129446A1 (en) | 2018-10-29 | 2020-04-30 | University Of Iowa Research Foundation | Respiratory syncytial virus (rsv) polyanhydride nanoparticle vaccine |
| PE20211469A1 (es) * | 2018-11-13 | 2021-08-05 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| WO2020175660A1 (ja) | 2019-02-28 | 2020-09-03 | Ｋｍバイオロジクス株式会社 | Ｒｓｖ ｆ／ｇキメラワクチン |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
| JP7818504B2 (ja) | 2019-09-04 | 2026-02-20 | ユニヴァーシティ オブ ワシントン | パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用 |
| TW202600603A (zh) | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
| AU2020402106A1 (en) | 2019-12-11 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mumps and Measles virus immunogens and their use |
| US20230086093A1 (en) * | 2019-12-23 | 2023-03-23 | Mitsubishi Tanabe Pharma Corporation | Mutant rsv f protein and use thereof |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| KR20220133911A (ko) * | 2020-01-30 | 2022-10-05 | 모더나티엑스, 인크. | 호흡기 바이러스 면역화 조성물 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US12679870B2 (en) | 2020-04-29 | 2026-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant human metapneumovirus F proteins and their use |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| AU2021279079A1 (en) * | 2020-05-29 | 2022-12-15 | Board Of Regents, The University Of Texas System | Engineered coronavirus spike (s) protein and methods of use thereof |
| WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
| JP2022023813A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
| JP2022023814A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のｒｓｖタンパク質の精製方法 |
| CN112226444B (zh) * | 2020-08-25 | 2022-11-04 | 北京交通大学 | 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品 |
| JP7822149B2 (ja) | 2020-10-02 | 2026-03-02 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| IL320367A (en) | 2020-10-09 | 2025-06-01 | Univ Texas | Prefusion-stabilized hmpv f proteins |
| KR20230097028A (ko) | 2020-10-28 | 2023-06-30 | 사노피 파스퇴르 | Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도 |
| CN112592928B (zh) * | 2020-12-31 | 2021-08-31 | 北京鼎成肽源生物技术有限公司 | 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法 |
| US20240228548A9 (en) * | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| AU2022251938A1 (en) | 2021-04-02 | 2023-11-16 | Bureau D’Études Biologiques Scientifiques Et Médicales | IMMUNOGENIC COMPOSITION CONTAINING AN ANTIGEN AND AN ADJUVANT COMPRISING AL-MOFs |
| US12304929B2 (en) * | 2021-04-12 | 2025-05-20 | Sk Bioscience Co., Ltd. | Recombinant RSV live vaccine strain and the preparing method thereof |
| WO2022221159A1 (en) * | 2021-04-15 | 2022-10-20 | Merck Sharp & Dohme Llc | Rotavirus vectors for heterologous gene delivery |
| IL310628A (en) * | 2021-08-10 | 2024-04-01 | Icosavax Inc | Virus-like particle vaccine for respiratory syncytial virus |
| KR20230047033A (ko) * | 2021-09-29 | 2023-04-06 | 에스케이바이오사이언스(주) | 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법 |
| WO2023091766A2 (en) * | 2021-11-19 | 2023-05-25 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| US12616747B2 (en) | 2021-12-03 | 2026-05-05 | Board Of Regents, The University Of Texas System | Stabilized beta-coronavirus antigens |
| KR102785012B1 (ko) * | 2021-12-14 | 2025-03-20 | 경희대학교 산학협력단 | Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| CN117715923A (zh) * | 2022-04-29 | 2024-03-15 | 北京新合睿恩生物医疗科技有限公司 | Rsv f蛋白突变体及其应用 |
| CN119452088A (zh) * | 2022-05-31 | 2025-02-14 | Vlp治疗日本公司 | 修饰疫苗设计开发 |
| EP4536274A1 (en) * | 2022-06-10 | 2025-04-16 | GlaxoSmithKline Biologicals SA | Rsv vaccination with trimeric rsv f fusion protein |
| WO2024041772A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
| KR20250054810A (ko) | 2022-09-29 | 2025-04-23 | 화이자 인코포레이티드 | Rsv f 단백질 삼량체를 포함하는 면역원성 조성물 |
| CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
| WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| CN120153078A (zh) | 2022-10-27 | 2025-06-13 | 辉瑞大药厂 | 编码rsv-f的rna分子及含所述rna分子的疫苗 |
| KR20250099727A (ko) * | 2022-11-04 | 2025-07-02 | 사노피 파스퇴르 인크 | 호흡기 세포융합 바이러스 rna 백신접종 |
| US20260193669A1 (en) * | 2022-11-09 | 2026-07-09 | Nykode Therapeutics ASA | Co-Expression of Constructs and Polypeptides |
| KR102531775B1 (ko) | 2022-11-11 | 2023-05-15 | 대한민국 | Rsv f 항체 또는 이의 항원 결합 단편 |
| CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
| WO2024115561A1 (en) * | 2022-12-01 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Vaccination against rsv |
| JP2026500218A (ja) | 2022-12-11 | 2026-01-06 | ファイザー・インク | インフルエンザおよびｒｓｖに対する免疫原性組成物 |
| JP2026503111A (ja) * | 2023-01-17 | 2026-01-27 | ザ スクリプス リサーチ インスティテュート | 操作されたパラミクソウイルス可溶性融合（ｆ）タンパク質及び関連するワクチン |
| CN120548194A (zh) | 2023-01-18 | 2025-08-26 | 辉瑞公司 | 针对呼吸道疾病的疫苗 |
| AU2023427858A1 (en) * | 2023-02-03 | 2025-05-15 | Vernagen, LLC | Respiratory syncytial virus mrna vaccine |
| WO2024164020A2 (en) * | 2023-02-03 | 2024-08-08 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting paramyxoviridae fusion to a target cell |
| KR20250152090A (ko) * | 2023-02-21 | 2025-10-22 | 엠에스디 인터내셔널 비즈니스 게엠베하 | 이종 삼량체화 도메인이 없는 안정화된 삼량체 rsv 융합 단백질 |
| WO2024175040A1 (en) * | 2023-02-22 | 2024-08-29 | Everest Medicines (China) Co., Ltd. | RSV mRNA VACCINES |
| US20260232787A1 (en) * | 2023-03-17 | 2026-08-13 | Westvac Biopharma Co., Ltd. | Vaccine against respiratory syncytial virus infection |
| CN116536357A (zh) * | 2023-04-17 | 2023-08-04 | 中国医学科学院输血研究所 | 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法 |
| CN118108812B (zh) * | 2023-05-04 | 2025-04-15 | 国药中生生物技术研究院有限公司 | Rsv f蛋白的突变体 |
| CN118930654A (zh) * | 2023-05-12 | 2024-11-12 | 中国科学院微生物研究所 | 一种呼吸道合胞病毒抗原制备方法和应用 |
| CN118994329A (zh) * | 2023-05-18 | 2024-11-22 | 北京微星生物科技有限公司 | 融合前rsv f蛋白及其应用 |
| CN117050149B (zh) * | 2023-05-19 | 2025-12-12 | 珠海丽凡达生物技术有限公司 | 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用 |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| WO2024240267A1 (zh) * | 2023-05-25 | 2024-11-28 | 江苏瑞科生物技术股份有限公司 | 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽 |
| AU2024287014A1 (en) * | 2023-06-07 | 2026-01-22 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine composition, method and use thereof |
| EP4727955A1 (en) * | 2023-06-16 | 2026-04-22 | GlaxoSmithKline Biologicals S.A. | Cysteine-substituted rsv-f proteins |
| EP4736848A1 (en) | 2023-06-28 | 2026-05-06 | Shanghai Regenelead Therapies Co., Ltd. | Pharmaceutical composition containing cationic lipid and use thereof |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| CN119431524A (zh) * | 2023-08-07 | 2025-02-14 | 北京新合睿恩生物医疗科技有限公司 | Rsv融合前构象f蛋白的突变体及其应用 |
| WO2025092933A1 (zh) * | 2023-10-31 | 2025-05-08 | 上海蓝鹊生物医药有限公司 | 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用 |
| KR20260112755A (ko) | 2023-11-13 | 2026-07-20 | 시추안 클로버 바이오파마슈티컬스, 인크. | Rsv 백신 조성물, 방법 및 이의 용도 |
| WO2025103414A1 (zh) | 2023-11-14 | 2025-05-22 | 上海瑞宏迪医药有限公司 | 一种脂质纳米粒的制备方法和应用 |
| CN120022355A (zh) * | 2023-11-22 | 2025-05-23 | 长春百克生物科技股份公司 | 一种mRNA疫苗及其应用 |
| CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| KR20250094574A (ko) * | 2023-12-15 | 2025-06-25 | 에스케이바이오사이언스(주) | 변이 rsv 단백질 |
| KR102816014B1 (ko) * | 2023-12-20 | 2025-06-02 | 에스케이바이오사이언스(주) | Rsv 의 가용성 f 단백질을 생성하기 위한 재조합 전구체 폴리펩티드 및 이의 이용 |
| CN117586425B (zh) * | 2024-01-19 | 2024-06-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用 |
| CN117567652B (zh) * | 2024-01-19 | 2024-05-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原 |
| CN117586357B (zh) * | 2024-01-19 | 2024-07-09 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117645655B (zh) * | 2024-01-26 | 2024-05-24 | 普大生物科技(泰州)有限公司 | 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法 |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN118440937B (zh) * | 2024-04-09 | 2025-02-25 | 嘉译生物医药(杭州)有限公司 | 新型的人合胞病毒RSV B mRNA疫苗 |
| CN118580323B (zh) * | 2024-05-22 | 2025-06-17 | 苏州聚微生物科技有限公司 | Rsv融合前f蛋白的突变体及其制备和应用 |
| CN118496324B (zh) * | 2024-05-22 | 2025-10-21 | 苏州聚微生物科技有限公司 | RSV pre-F突变体及其生产方法和用途 |
| CN118406159B (zh) * | 2024-05-22 | 2025-07-08 | 苏州聚微生物科技有限公司 | RSV pre-F截短体及其生产方法和应用 |
| CN118480560B (zh) * | 2024-07-09 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119074910A (zh) * | 2024-08-30 | 2024-12-06 | 中国医学科学院病原生物学研究所 | 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法 |
| CN118725053B (zh) * | 2024-09-03 | 2024-12-24 | 北京民海生物科技有限公司 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
| WO2026083454A1 (en) * | 2024-10-19 | 2026-04-23 | Mynvax Private Limited | Disulphide-linked oligomerization domain, polypeptides, and uses thereof |
| CN119161495B (zh) * | 2024-11-20 | 2025-04-11 | 传信生物医药(苏州)有限公司 | 呼吸道合胞病毒重构多肽及其应用 |
| CN119176859B (zh) * | 2024-11-26 | 2025-03-14 | 北京成大天和生物科技有限公司 | 呼吸道合胞病毒f蛋白突变体及其应用 |
| CN120248057B (zh) * | 2024-12-26 | 2025-12-02 | 北京华诺泰生物医药科技有限公司 | 一种呼吸道合胞病毒f蛋白突变体及其应用 |
| WO2026158514A1 (zh) * | 2025-01-26 | 2026-07-30 | 神州细胞工程有限公司 | 呼吸道合胞病毒f蛋白突变体及其用途 |
| CN122011136A (zh) * | 2026-04-13 | 2026-05-12 | 北京民海生物科技有限公司 | 一种融合前人偏肺病毒f蛋白的突变体及其应用 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US472209A (en) | 1892-04-05 | Vacuum-pan | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA1336955C (en) * | 1988-09-20 | 1995-09-12 | Peter R. Paradiso | Respiratory syncytial virus: vaccines and diagnostic assays |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| PT729473E (pt) | 1993-11-17 | 2001-02-28 | Deutsche Om Arzneimittel Gmbh | Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1086234A1 (en) * | 1998-06-10 | 2001-03-28 | Incyte Pharmaceuticals, Inc. | New human carboxypeptidase inhibitor |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US20040096451A1 (en) | 2002-07-25 | 2004-05-20 | Young James F. | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
| US20030232061A1 (en) | 2001-10-18 | 2003-12-18 | Fouchier Ronaldus Adrianus Maria | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| EP1372706B1 (en) | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US7041489B2 (en) | 2001-10-01 | 2006-05-09 | The Uab Research Foundation | Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof |
| DK1719511T3 (da) | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf |
| TWI344991B (en) | 2002-02-21 | 2011-07-11 | Medimmune Vaccines Inc | Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences |
| EP1558747B1 (en) | 2002-10-16 | 2009-10-14 | The Scripps Research Institute | Glycoprotein synthesis |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| CA2523657A1 (en) | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| WO2005111621A2 (en) | 2004-04-16 | 2005-11-24 | Uab Research Foundation | Molecular scaffolds for hiv-1 epitopes |
| US8647818B2 (en) | 2005-02-18 | 2014-02-11 | UAB Research Foundation, University of Alabama—Birmingham | Molecular scaffolds for HIV-1 immunogens |
| CN101548009A (zh) | 2005-03-10 | 2009-09-30 | 米迪缪尼有限公司 | 偏肺病毒株及其在疫苗制备和作为抗原序列表达载体的应用以及增殖该病毒的方法 |
| US7728106B2 (en) | 2005-07-01 | 2010-06-01 | University Of Maryland Biotechnology Institute | HIV-1 glycopeptides and derivatives; preparation and applications thereof |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| US20100068217A1 (en) | 2006-08-25 | 2010-03-18 | Kwong Peter D | Epitope-transplant scaffolds and their use |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US20090017517A1 (en) | 2007-07-13 | 2009-01-15 | Medimmune, Llc | Preparation of Negative-Stranded RNA Viruses by Electroporation |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| WO2010075491A2 (en) * | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| SG176807A1 (en) * | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
| PL2445526T3 (pl) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Rekombinowane antygeny rsv |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011043643A1 (en) | 2009-10-06 | 2011-04-14 | Medimmune Ltd | Rsv-specific binding molecule |
| WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
| RS56748B1 (sr) * | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Pre-fuzioni rsv f antigeni |
| CN102210860B (zh) | 2011-05-31 | 2012-11-21 | 昆明理工大学 | 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法 |
| ES2395677B1 (es) * | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
| SG11201500573RA (en) * | 2012-08-06 | 2015-02-27 | Glaxosmithkline Biolog Sa | Method for eliciting in infants an immune response against rsv and b. pertussis |
| KR20150085843A (ko) * | 2012-11-20 | 2015-07-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Rsv f 융합전 삼합체 |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EP4421177A3 (en) * | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US9856313B2 (en) | 2013-03-15 | 2018-01-02 | Xiamen University | Epitope of RSV fusion protein and antibody recognizing the same |
| PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
-
2014
- 2014-03-13 EP EP24174501.7A patent/EP4421177A3/en active Pending
- 2014-03-13 KR KR1020157025199A patent/KR102450375B1/ko active Active
- 2014-03-13 CN CN201480027499.3A patent/CN105473604B/zh active Active
- 2014-03-13 KR KR1020257003905A patent/KR20250023601A/ko active Pending
- 2014-03-13 SI SI201432090T patent/SI2970398T1/sl unknown
- 2014-03-13 EP EP14775224.0A patent/EP2970398B1/en active Active
- 2014-03-13 WO PCT/US2014/026714 patent/WO2014160463A1/en not_active Ceased
- 2014-03-13 MX MX2015013065A patent/MX385818B/es unknown
- 2014-03-13 JP JP2016502221A patent/JP6703475B2/ja active Active
- 2014-03-13 SM SM20240297T patent/SMT202400297T1/it unknown
- 2014-03-13 KR KR1020227033808A patent/KR102766946B1/ko active Active
- 2014-03-13 RU RU2015142981A patent/RU2761631C2/ru active
- 2014-03-13 ES ES14775224T patent/ES2981623T3/es active Active
- 2014-03-13 RS RS20240825A patent/RS65760B1/sr unknown
- 2014-03-13 HR HRP20240996TT patent/HRP20240996T1/hr unknown
- 2014-03-13 FI FIEP14775224.0T patent/FI2970398T3/fi active
- 2014-03-13 PL PL14775224.0T patent/PL2970398T3/pl unknown
- 2014-03-13 DK DK14775224.0T patent/DK2970398T3/da active
- 2014-03-13 US US14/776,651 patent/US10017543B2/en active Active
- 2014-03-13 CN CN202110068562.XA patent/CN112851766A/zh active Pending
- 2014-03-13 HU HUE14775224A patent/HUE067333T2/hu unknown
- 2014-03-13 AU AU2014243756A patent/AU2014243756B2/en active Active
- 2014-03-13 LT LTEPPCT/US2014/026714T patent/LT2970398T/lt unknown
- 2014-03-13 CA CA2902877A patent/CA2902877C/en active Active
- 2014-03-13 PT PT147752240T patent/PT2970398T/pt unknown
- 2014-03-13 CA CA3291895A patent/CA3291895A1/en active Pending
-
2015
- 2015-09-11 MX MX2021010519A patent/MX2021010519A/es unknown
-
2018
- 2018-07-02 US US16/025,858 patent/US11130785B2/en active Active
- 2018-12-21 AU AU2018282476A patent/AU2018282476B2/en active Active
-
2020
- 2020-02-12 JP JP2020021468A patent/JP7043530B2/ja active Active
-
2021
- 2021-03-08 AU AU2021201468A patent/AU2021201468B2/en active Active
- 2021-09-17 US US17/478,533 patent/US20220002351A1/en not_active Abandoned
-
2022
- 2022-03-16 JP JP2022041006A patent/JP7503588B2/ja active Active
-
2023
- 2023-02-09 AU AU2023200712A patent/AU2023200712B2/en active Active
- 2023-09-11 US US18/464,786 patent/US11981707B2/en active Active
-
2024
- 2024-06-10 JP JP2024093392A patent/JP2024107243A/ja active Pending
- 2024-12-30 US US19/005,704 patent/US20250368690A1/en active Pending
-
2025
- 2025-05-19 AU AU2025203614A patent/AU2025203614A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015142981A (ru) | Белки rsv в предшествующей слиянию конформации и их применение | |
| CA3146464C (en) | Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use | |
| TWI756828B (zh) | Rsv f蛋白突變體 | |
| JP7189014B2 (ja) | Ｒｓｖに対するワクチン | |
| JP6898024B2 (ja) | ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物 | |
| JP7614841B2 (ja) | 抗原性呼吸器合胞体ウイルスポリペプチド | |
| EP2928491B1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
| US20220185847A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| CN116096404A (zh) | 多肽、组合物及其用于治疗或限制感染发展的用途 | |
| JP2013517783A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| US20240181034A1 (en) | Human metapneumo virus vaccine | |
| KR20170105107A (ko) | 항원-특이적인 t-세포 반응을 도출하는 데 사용하기 위한 면역원성 단백질 및 조합 아주반트를 포함하는 백신 조성물 | |
| JP2024508683A5 (enExample) | ||
| KR20240024064A (ko) | 코로나바이러스 및 인플루엔자 조성물 그리고 이의 사용 방법 | |
| EP4203998A1 (en) | Immunogenic coronavirus fusion proteins and related methods | |
| JP2026062907A (ja) | 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用 | |
| US20230218739A1 (en) | Vaccine compositions, methods, and uses thereof | |
| KR20260007370A (ko) | 코로나바이러스 및 인플루엔자 조성물 및 이들을 사용하는 방법 | |
| HK40098178A (en) | Human metapneumovirus vaccine | |
| AU2024214179A1 (en) | Rsv f vaccine formulations | |
| TWI531583B (zh) | 用以對抗ｐｒｒｓｖ之融合胜肽及ｐｒｒｓｖ疫苗 | |
| EA052740B1 (ru) | Иммуногенные слитые белки коронавируса и связанные с ними способы | |
| TH114418A (th) | วัคซีน |